ENPP2 and idiopathic pulmonary fibrosis: This applies particularly to idiopathic pulmonary fibrosis, for which the ATX inhibitor GLPG1690 (ziritaxestast) and LPAR1 receptor antagonist BMS-986020 have entered clinical trials [20,21].